TABLE 2

Two clinical R. mucilaginosa strains were susceptible to voriconazole, while no environmental strains were susceptible to voriconazole and all R. mucilaginosa strains were resistant to fluconazolea

StrainZone of inhibition (mm), susceptibility rating
VoriconazoleFluconazole
Cryptococcus
    H9928, S18, SDD
    NIH 11729, S20, S
    NIH 19234, S18, SDD
    NIH 43037, S32, S
Rhodotorula, environmental
    ARY 1150, R0, R
    ARY 1160, R0, R
    ARY 12010, R0, R
    ARY 1260, R0, R
    ARY 16210, R0, R
    ARY 2000, R0, R
    ARY 2250, R0, R
    ARY 2500, R0, R
Rhodotorula, clinical
    ARY 2010, R0, R
    ARY 20223, S0, R
    ARY 2030, R0, R
    ARY 20429, S0, R
    ARY 2050, R0, R
    ARY 2060, R0, R
    ARY 2070, R0, R
    ARY 2080, R0, R
  • a C. neoformans (H99, NIH 117 to 430 as indicated), R. mucilaginosa environmental (ARY 115 to 250 as indicated), and R. mucilaginosa clinical (ARY 201 to 208 as indicated) strains were grown in YPD medium overnight at 30°C, and equivalent cell amounts were plated onto Mueller-Hinton plates. Two disks for each antifungal agent were placed onto each plate, and the plates were incubated for 2 days at 37°C before imaging and measuring. Zone-of-inhibition measurements (in millimeters) are listed followed by the susceptibility rating of susceptible (S), susceptible dose dependent (SDD), or resistant (R) as defined previously by Pfaller et al. (1). All of the C. neoformans strains were susceptible to voriconazole (zone of inhibition, over 17 mm [1]). Two environmental R. mucilaginosa exhibited zones of inhibition in response to voriconazole, but with zones of inhibition of less than 14 mm, they are considered resistant (1). Two clinical R. mucilaginosa strains were susceptible to voriconazole. Two of the C. neoformans strains were susceptible to fluconazole, and two were susceptible dose dependent (S = 19 mm; SDD = 15 to 18 mm [1]). None of the R. mucilaginosa strains yielded any zones of inhibition in response to fluconazole.